Delix Therapeutics Partners with the National Institute on Drug Abuse (NIDA) to Advance Research on Non-Hallucinogenic Therapies to Treat Substance Use Disorders Post published:December 7, 2021 Post category:Press Release
Delix Therapeutics Announces Appointment of Dr. John Krystal to Scientific & Strategic Advisory Board Post published:October 25, 2021 Post category:Press Release
Delix Therapeutics Closes $70 Million Series A Financing to Advance Pipeline of Novel Psychoplastogen Therapeutics to Treat Brain Disorders Post published:September 27, 2021 Post category:Press Release
Delix Therapeutics Expands Executive Leadership Team Post published:July 6, 2021 Post category:Press Release
Delix Therapeutics Announces Scientific & Strategic Advisory Board Appointments Post published:June 4, 2021 Post category:Press Release
Delix Therapeutics Co-Founder Publishes Groundbreaking Study Demonstrating Therapeutic Potential for a Psychedelic AnalogāWithout Hallucinogenic Effects Post published:April 28, 2021 Post category:Press Release